Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
about
sameAs
ALK Signaling and Target Therapy in Anaplastic Large Cell LymphomaImmunoaffinity profiling of tyrosine phosphorylation in cancer cellsAnaplastic lymphoma kinase: signalling in development and diseasep130Cas mediates the transforming properties of the anaplastic lymphoma kinaseOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesThe Newly Identified T Helper 22 Cells Lodge in LeukemiaThe emerging role of Twist proteins in hematopoietic cells and hematological malignanciesTargeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastomaInhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3.Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)Nucleophosmin overexpression is associated with poor survival in astrocytoma.Novel mRNA-containing cytoplasmic granules in ALK-transformed cells.NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein.High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genesDNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH.The heterogeneous landscape of ALK negative ALCL.Research progresses in the pathogenesis of anaplastic large cell lymphoma.SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancerSTAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytesThe tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complexCoordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions.Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.In vivo interference with Skp1 function leads to genetic instability and neoplastic transformationThe heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.ALK-driven tumors and targeted therapy: focus on crizotinibCD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.A novel role for IL-22R1 as a driver of inflammation.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.STAT3: a multifaceted oncogene.Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targetsFunctional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.Cooperative Cross-Talk between Neuroblastoma Subtypes Confers Resistance to Anaplastic Lymphoma Kinase Inhibition.
P2860
Q21129306-E4DFA21C-6501-4088-A49C-78DC703E3CC7Q21735929-82E9F101-57AD-4964-9D4B-3B8CE3B75B41Q24312329-A5533EFD-71D7-4242-BB68-301C3E1570A5Q24315788-88100CFA-6F2E-4BCD-869C-6963A49B46BDQ26768158-AF5DD54D-CE83-4570-92E1-45B90F95F506Q26799454-9F697B2D-BFF0-4AA9-B6AB-0BBD9963E448Q26822434-36EFAFEE-3416-47BA-9708-ADAE38577A2EQ27022941-9CDE55A5-E893-4C2B-A64F-AC82443784CCQ27851640-0BDE37D5-3D71-4F27-90F4-7AB6234DC463Q28253106-5B0E4986-E84C-4E01-B8F2-01E00D3B1C64Q28588852-50AD4EDA-52BB-4D56-BFD8-88A0DC753D2DQ30300125-D6CA1724-5BF9-4E67-B1BD-07FE4571A86AQ30498700-F17EC36F-5995-4307-97D9-87D71DE1F36CQ30831857-4728EC9F-1C1E-4785-96B9-2C5E4938652AQ30911799-424EF1C2-FA35-4BA8-8DEA-2F1FBBDB6CB1Q31164878-5563F53C-981C-4923-8CCE-6B869CBBF7D0Q33258311-BCE94F7E-202F-4732-A06F-8794910529D4Q33267003-56BF8F85-E37A-428E-844F-641BF240193CQ33567012-5FE9059E-6395-42B4-AD5F-4048DED32583Q33579708-DC9C56A9-ECBB-4638-BF72-BD0D6E9EB6D7Q33715489-78FA8E93-F9BC-4B91-A899-E3B967816AB1Q33784496-B9CE811A-0305-4B25-83A4-2E4F23705842Q33924261-4EFE9975-4196-46F8-9DB2-556D242EA32CQ34016520-8B8649EC-C1C5-47F8-AA8D-68CC4DE254E8Q34022050-491AD9A1-C33C-4E61-A1C7-61000C5B1D7DQ34057987-6CB5E438-1A29-4CAD-AAA8-04FF38C74FBDQ34136298-57426340-F542-46CA-B48A-CF738C93BEB0Q34221605-B6B64E93-1A70-4F9F-86B3-89012F5A7191Q34286428-F1927068-A0BA-4FAC-9608-15BDABAFF0FAQ34297784-D67C3253-7A85-4092-B1B1-7CE8067AB589Q34361391-B0235A95-4C0D-4798-BC16-22E02843E5A6Q34414378-2E124B85-C462-4C60-9485-885D3224856AQ34460823-05544688-3AC7-4C36-96C9-18B40BB4AB01Q34542109-5338F43F-C62B-4A92-AE9F-C4A0D248E190Q34648812-9D1587DD-C275-4D3E-9FBE-25B66D5527EFQ34657347-EF2E7DA0-4256-4257-8A82-F51F6CF3C548Q34771828-B645FB08-E830-47CD-934E-EEE0C301BA60Q34898306-41537E8D-2327-4DD5-B741-A37D7B038B3CQ35131224-BB4B5A7A-33EB-4535-871B-04584FE726F6Q35180335-58F16459-A4CC-47CE-B406-3940C01815E0
P2860
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@ast
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@en
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@nl
type
label
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@ast
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@en
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@nl
prefLabel
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@ast
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@en
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@nl
P2093
P50
P356
P1433
P1476
Anaplastic lymphoma kinase (AL ...... opoietic cells from cell death
@en
P2093
Alberto Zamo
Giorgio Inghirami
Jennifer Howes
Marco Chilosi
P2888
P304
P356
10.1038/SJ.ONC.1205152
P407
P577
2002-02-01T00:00:00Z
P5875
P6179
1042163942